MGB Biopharma licensed to treat deadly infections

Narrative

MGB Biopharma is advancing a truly novel class of anti-infective drug candidates with the potential to treat a number of the most important resistant pathogens impacting human health today. One of these candidates, MGB-BP-3, is a synthetic polyamide which has been shown to bind strongly and selectively to the minor groove of bacterial DNA. MGB-BP-3 has shown highly potent activity, superior to vancomycin, against all Gram-positive bacteria tested, including Clostridium difficile (C. difficile) and Methicillin-resistant Staphylococcus aureus (MRSA). The University of Strathclyde continues to explore other anti-infective compounds from its MGB platform against viral, parasitic and Gram-negative infections. While less advanced than MGB-BP-3, these programmes are already showing some highly encouraging results.

Impact status	Open
Category of impact	Economic and commerce, Health and welfare - new products, guidelines and services